Therapeutic nanoparticles and their targeted delivery applications

AA Yetisgin, S Cetinel, M Zuvin, A Kosar, O Kutlu - Molecules, 2020 - mdpi.com
Nanotechnology offers many advantages in various fields of science. In this regard,
nanoparticles are the essential building blocks of nanotechnology. Recent advances in …

[HTML][HTML] Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases

C Saraiva, C Praça, R Ferreira, T Santos… - Journal of controlled …, 2016 - Elsevier
The blood–brain barrier (BBB) is a vital boundary between neural tissue and circulating
blood. The BBB's unique and protective features control brain homeostasis as well as ion …

[HTML][HTML] The role of dopamine in the brain-lessons learned from Parkinson's disease

D Meder, DM Herz, JB Rowe, S Lehéricy, HR Siebner - Neuroimage, 2019 - Elsevier
Parkinson's disease causes a characteristic combination of motor symptoms due to
progressive neurodegeneration of dopaminergic neurons in the substantia nigra pars …

Neuroimaging of Parkinson's disease: Expanding views

CP Weingarten, MH Sundman, P Hickey… - … & Biobehavioral Reviews, 2015 - Elsevier
Advances in molecular and structural and functional neuroimaging are rapidly expanding
the complexity of neurobiological understanding of Parkinson's disease (PD). This review …

Social symptoms of Parkinson's disease

MTM Prenger, R Madray, K Van Hedger… - Parkinson's …, 2020 - Wiley Online Library
Parkinson's disease (PD) is typically well recognized by its characteristic motor symptoms
(eg, bradykinesia, rigidity, and tremor). The cognitive symptoms of PD are increasingly being …

Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinson's disease

C O'Callaghan, FH Hezemans, R Ye, C Rua, PS Jones… - Brain, 2021 - academic.oup.com
Cognitive decline is a common feature of Parkinson's disease, and many of these cognitive
deficits fail to respond to dopaminergic therapy. Therefore, targeting other neuromodulatory …

Role of nanomedicine-based therapeutics in the treatment of CNS disorders

ZH Guo, S Khattak, MA Rauf, MA Ansari, MN Alomary… - Molecules, 2023 - mdpi.com
Central nervous system disorders, especially neurodegenerative diseases, are a public
health priority and demand a strong scientific response. Various therapy procedures have …

The role of high‐field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward

S Lehericy, DE Vaillancourt, K Seppi… - Movement …, 2017 - Wiley Online Library
Historically, magnetic resonance imaging (MRI) has contributed little to the study of
Parkinson's disease (PD), but modern MRI approaches have unveiled several …

MPTP‐induced changes in hippocampal synaptic plasticity and memory are prevented by memantine through the BDNF‐TrkB pathway

G Zhu, J Li, L He, X Wang… - British journal of …, 2015 - Wiley Online Library
Background and Purpose Mild cognitive deficit in early P arkinson's disease (PD) has been
widely studied. Here we have examined the effects of memantine in preventing memory …

Acute and chronic cognitive effects of levodopa and dopamine agonists on patients with Parkinson's disease: a review

M Poletti, U Bonuccelli - Therapeutic advances in …, 2013 - journals.sagepub.com
The spatiotemporal progression of dopamine depletion in Parkinson's disease (PD)
provides a special model for assessing dopaminergic effects on neural systems with …